Clinical activity of durvalumab and savolitinib in MET-driven, metastatic papillary renal cancer.

Cristina Suarez Rodriguez,James Larkin,Poulam M. Patel,Begoña P. Valderrama,Alejo Rodriguez-Vida,Hilary Glen,Fiona C. Thistlethwaite,Christy Ralph,Gopalakrishnan Srinivasan,María José Méndez-Vidal,Abigail Carter,Charlotte Tyson,Aaron Prendergast,Kelly Mousa,Thomas Powles

Clinical activity of durvalumab and savolitinib in MET-driven, metastatic papillary renal cancer.

2021

Cristina Suarez Rodriguez
James Larkin
Poulam M. Patel
Begoña P. Valderrama
Alejo Rodriguez-Vida
Hilary Glen
Fiona C. Thistlethwaite
Christy Ralph
Gopalakrishnan Srinivasan
María José Méndez-Vidal
Abigail Carter
Charlotte Tyson
Aaron Prendergast
Kelly Mousa
Thomas Powles

4511Background: Savolitinib is a potent and selective MET inhibitor with activity in MET-driven papillary renal cancer (PRC). Durvalumab is a PD-L1 inhibitor which has been tested in combination wi...

Keywords:

Internal medicine
Medicine
Savolitinib
Oncology
Cancer
Durvalumab

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations